PHARMACEUTICAL INDUSTRY SYMPOSIUM 2 BY ZENTIVA

Daruph - Added Value Dasatinib in treatment of Leukemia

Chronic myeloid leukemia (CML)- disease overview and Tyrosine kinase inhibitors (TKI) differentiation
Prof.LIdija Cevreska- University Clinic for Hematology-Skopje, R.N.Macedonia

Daruph (Dasatinibe anhydrous) for the treatment of chronic myeloid leukemia - Focus on clinical pharmacokinetics and pharmacodynamics